Home › Cancro al seno triplo negativo › Maryland › Baltimore
Studi clinici su Cancro al seno triplo negativo a Baltimore, MD
12 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi a Baltimore e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
In reclutamentoFase 3
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
In reclutamentoFase 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
In reclutamentoFase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
In reclutamentoFase 1
- United Theranostics, Glen Burnie · a 9 mi di distanza
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
In reclutamentoFase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
In reclutamentoFase 3
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- e altri 1
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
In reclutamentoFase 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
In reclutamentoFase 2/3
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
In reclutamentoFase 1
- United Theranostics, Glen Burnie · a 9 mi di distanza
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
In reclutamentoFase 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
In reclutamentoFase 2
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
In reclutamentoFase 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Studi su Cancro al seno triplo negativo in altre città
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Altri studi a Baltimore
- Cancro del polmone non a piccole cellule60 studi
- Cancro al seno47 studi
- Cancro alla prostata43 studi
- Cancro ai polmoni40 studi
- Cancro (tutti i tipi)37 studi
- Cancro pancreatico31 studi
- Cancro colorettale31 studi
- Cancro metastatico28 studi
- Obesità26 studi
- Cancro della vescica24 studi
- Insufficienza cardiaca24 studi
- Cancro ovarico22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.